Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02236195
Title Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Mocetinostat

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama Birmingham Alabama 35294 United States Details
City of Hope National Medical Center Duarte California 91010 United States Details
Florida Cancer Specialists Fort Myers Florida 33905 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Johns Hopkins University Baltimore Maryland 21287 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of Rochester Rochester New York 14627 United States Details
University of North Carolina Chapel Hill North Carolina 27599 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Ohio State University Columbus Ohio 43210 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field